GRI Bio (GRI) Capital Leases (2020 - 2021)
GRI Bio (GRI) posted quarterly Capital Leases of $146000.0 for Q1 2021, down 14.12% quarter-over-quarter from $170000.0 in Q4 2020.
GRI Bio (GRI) Capital Leases (2020 - 2021) Analysis & Trends
GRI Bio's Capital Leases history runs 2 years deep, the most recent figure standing at $146000.0 for Q1 2021.
- In Q1 2021, Capital Leases changed N/A year-over-year to $146000.0; the TTM figure through Mar 2021 stood at $146000.0 (changed N/A YoY), while the FY2020 annual figure was $170000.0, changed N/A from the prior year.
- Capital Leases for Q1 2021 stood at $146000.0, down from $170000.0 in the prior quarter.
- The five-year high for Capital Leases was $170000.0 in Q4 2020, with the low at $146000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 146,000.00 |
| Dec 31, 2020 | 170,000.00 |